Literature DB >> 15461898

Basal insulin therapy.

John N Clore1, Linda Thurby-Hay.   

Abstract

The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with a major stumbling block being the perceived complexity of insulin. However, this complexity can be easily overcome by separation of insulin administration into its two components: basal and bolus therapy. An understanding of the role of basal insulin in the regulation of glucose and the development of strategies to implement basal insulin therapy can provide a transition that is rational and highly effective in most patients. The strategy also offers a unique approach to diabetes education, which permits a focused and patient-specific correction to glucose abnormalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15461898     DOI: 10.1007/s11892-004-0035-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  23 in total

Review 1.  Evening insulin strategy.

Authors:  M C Riddle
Journal:  Diabetes Care       Date:  1990-06       Impact factor: 19.112

2.  Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus.

Authors:  Edith Schober; Eugen Schoenle; Jacobus Van Dyk; Karin Wernicke-Panten
Journal:  J Pediatr Endocrinol Metab       Date:  2002-04       Impact factor: 1.634

3.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Authors:  M Lepore; S Pampanelli; C Fanelli; F Porcellati; L Bartocci; A Di Vincenzo; C Cordoni; E Costa; P Brunetti; G B Bolli
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

4.  Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.

Authors:  H Yki-Järvinen; L Ryysy; K Nikkilä; T Tulokas; R Vanamo; M Heikkilä
Journal:  Ann Intern Med       Date:  1999-03-02       Impact factor: 25.391

5.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

6.  Effect of fatty acids on glucose production and utilization in man.

Authors:  E Ferrannini; E J Barrett; S Bevilacqua; R A DeFronzo
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

7.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin.

Authors:  K Rebrin; G M Steil; L Getty; R N Bergman
Journal:  Diabetes       Date:  1995-09       Impact factor: 9.461

10.  Effects of acute insulin excess and deficiency on gluconeogenesis and glycogenolysis in type 1 diabetes.

Authors:  Guenther Boden; Peter Cheung; Carol Homko
Journal:  Diabetes       Date:  2003-01       Impact factor: 9.461

View more
  2 in total

1.  Uncovering undetected hypoglycemic events.

Authors:  Jeff Unger
Journal:  Diabetes Metab Syndr Obes       Date:  2012-03-08       Impact factor: 3.168

2.  Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.

Authors:  Yasuhiko Iwamoto; Per Clauson; Tomoyuki Nishida; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2012-09-14       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.